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Abstract 
As medication therapy management (MTM) continues to grow in the profession of pharmacy, careful consideration as to areas for 
positive patient impact is warranted. Given the current gaps in preconception care in the United States, and the accessibility and 
expertise of the pharmacist, MTM interventions related to preconception care may be valuable. This paper  describes potential for 
pharmacist intervention in several different areas of preconception care. Notably, targeted medication reviews may be appropriate 
for interventions such as folic acid recommendations, teratogenic/category X medication management, immunizations, and disease 
state management. Comprehensive medication reviews may be warranted for selected disease states due to complexity of 
interventions, such the management of diabetes.  Comprehensive medication reviews may also be warranted if several targeted 
interventions are necessary, or if there are a several medications or disease states requiring intervention. Pharmacists also have 
important roles in screening, support, and referrals needed for preconception care in the context of MTM.  Patients may benefit 
substantially from pharmacist-directed MTM services related to preconception care.   In addition, depending on clinical pharmacy 
service contracts and billing opportunities, pharmacists may be reimbursed for providing these services, generating sustainable 
revenue while fulfilling an important public health need. 
 
 
Introduction 
In recent years, medication therapy management (MTM) 
services have continued to grow at the state and national 
levels.
1-3
 Other examples of MTM services have continued to 
expand as well, including disease state management (DSM), 
care transition efforts, and pharmacogenomic management.
4-
8 
 Specific patient populations may be targeted or eligible for 
select services, such as those at high risk for hospital 
readmission in a care transitions program, or those suffering 
from chronic disease states that are enrolled into a DSM 
program.
4,5
 The Centers for Medicare and Medicaid Services 
define both the comprehensive medication review (CMR) and 
the targeted medication review (TMR) as required services 
for Medicare Part D MTM programs.
9
  Other third-party 
payers, such as state managed Medicaid programs, have also 
begun to reimburse pharmacists for providing MTM services.
1
  
CMRs may be useful in situations such as care transitions, 
where many disease states and medications may need to be 
reviewed.
4
 Alternatively, TMRs may be more practical when 
one medication or disease state is specifically reviewed, such 
as during an over-the-counter or prescription drug 
intervention.  Private insurance plans and government-based  
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programs may offer MTM billing for CMRs and TMRs, with 
billing commonly seen through a computerized clinical 
platform.
1,3 
As one example of such a platform, 
OutcomesMTM (OutcomesMTM.com, Des Moines, IA) 
provides an opportunity to bill CMRs as well as TMRs, which 
may include recommending a specific therapy.  
 
An important public health priority that may be addressed 
through MTM services is the provision of preconception care. 
The objective of preconception care is to improve the health 
of all women of childbearing age before pregnancy to prevent 
future health problems.
10-12
  Interconception care, a subset of 
preconception care, focuses on the health of women 
between pregnancies;
10
  therefore, preconception care is not 
exclusively reserved for women who have never conceived.  
(The term “preconception care” will be used throughout the 
paper to denote both preconception and interconception 
care.)  
 
Preconception care comprises recognizing and addressing 
biomedical or behavioral issues that may pose a risk to the 
health of a woman or fetus.  These interventions should occur 
before conception or very early in the first trimester for 
greatest impact.
10,11 
 Since many women may not obtain 
prenatal care until the eleventh or twelfth week of 
pregnancy, preconception care helps to ensure that the 
window of opportunity for these needed interventions is not 
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missed.
13
 As about half of all pregnancies in the U.S. are 
unintended,
14 
 and with 43% of those occurring among 
women inconsistently using contraception,
15 
 it is important 
for health care professionals to highlight the need for 
preconception interventions even for those not intending to 
become pregnant.  It should be noted that these 
preconception care services also promote optimal health for 
all women.
10 
 
There are many potential roles for pharmacists to advance 
preconception care (Table 1).  Pharmacists are well-suited to 
impact preconception care interventions, either directly 
through MTM services or through referral and collaboration 
with other healthcare professionals.  The purpose of this 
paper is to highlight how proven preconception care 
interventions can be addressed through MTM. Opportunities 
for care are described below and categorized as potential 
TMRs or CMRs.  However, pharmacist judgment is necessary 
to appropriately select the correct level of intervention based 
on the complexity and number of related issues or services 
needed for an individual patient.  
 
The Need for Preconception Care   
In 2006, the Centers for Disease Control and Prevention (CDC) 
Preconception Care Work Group and the Select Panel on 
Preconception Care (SPPC) released goals (Table 2) and 
recommendations (Table 3) for preconception care.
10   
Fourteen proven intervention for preconception care were 
identified based on published literature and clinical practice 
guidelines (Table 4),
10,11
 although additional topics may also 
be considered as part of preconception care.
16 
 
The need for preconception care in the United States (U.S.) is 
great.
10-12
 The CDC and SPPC have recommended that 
preconception care be viewed as part of routine healthcare 
for all women of childbearing potential.
10,11  
 (There are 
several considerations for men in the preconception period
17 
which are outside of the scope of this paper.)  While the way 
the information is presented and the perceived benefits may 
differ among those contemplating a pregnancy and “non-
contemplators”, the intended outcomes are the same: to 
increase the intentionality of pregnancy and to improve a 
woman’s health status prior to pregnancy.
18 
 
The CDC has advocated that both clinical health and public 
health providers partner to provide preconception care to all 
women.
10   
However, current literature suggests that many 
patients are not routinely receiving the necessary 
preconception education, counseling or interventions.
10
  For 
example, according to a survey conducted by the Gallup 
Organization and the March of Dimes, about 40% of women 
aged 18-45 years reported taking a daily multivitamin or folic 
acid tablet; the percentage widely varied by age.  Among 
those who did not take daily folic acid supplementation, 
almost 90% of women surveyed indicated that they would be 
likely to do so if advised by a health care provider.  Yet, only 
12% of women aged 18-24 years, 41% of women aged 25-34 
years, and 35% of women aged 35-45 years reported 
receiving information about folic acid from a healthcare 
professional.
19
   
 
Opportunities for Pharmacist Intervention via TMR  
As many preconception-related interventions focus on one 
medication, intervention, or immunization at a time, it could 
be very valuable for pharmacists to engage in TMRs. Such 
services can be offered either at the point of dispensing, or in 
the form of a retrospective identification of a specific set of 
patients.  Several elements of preconception care are listed 
below that may be addressed through TMR.     
 
Folic Acid 
All women of childbearing potential are recommended to 
take 400 micrograms of folic acid daily to reduce the risk of 
neural tube defect.
20 
 As it is difficult to receive adequate 
amounts of folic acid through diet alone, women are 
recommended to take either a folic acid supplement or a 
multivitamin containing the recommended amount of folic 
acid.
21
  Certain groups should be advised to take greater 
doses of folic acid: women with diabetes (usually 4-5 
mg/day), using antiepileptic drug (usually 4 mg/day), or 
having experienced a previous neural tube defect-affected 
pregnancy (usually 4 mg/day).
20,22 
Teratogenic and Category X Medications 
Managing the use of teratogenic medications including 
antiepileptics, oral anticoagulants, and isotretinoin are also 
included among the interventions proposed by the CDC and 
SPPC.  It is recommended that a woman using antiepileptic 
medications, whether for seizure disorders or other 
conditions, should defer conception until her condition is 
well-controlled on the minimum dose of medication, 
preferably monotherapy.  Known potential teratogens should 
be avoided in the preconception period, if possible. She 
should also be provided education regarding increased folic 
acid supplementation as discussed above.
10,11,23,24 
  Warfarin is 
a known teratogen, and it is recommended to avoid warfarin 
exposure in early pregnancy.  Women should use a less 
teratogenic anticoagulant such a heparin prior to conception 
whenever possible, keeping in mind the risk/benefit ratio for 
patients with certain conditions like mechanical heart 
valves.
10,11,25
  Isotretinoin use is contraindicated during 
pregnancy; women of childbearing potential should ensure 
effective pregnancy prevention by utilizing two forms of 
contraception one month before, during, and for one month 
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after isotretinoin therapy.
10,11,26 
  While the iPLEDGE system is 
in place to minimize the risks associated with isotretinoin use 
among women of childbearing potential,
 27
 this type of 
program does not exist for all teratogenic medications. 
Finally, although not specifically included in the CDC and 
SPPC’s targeted intervention list, women of childbearing 
potential receiving Category X drugs such as statins, ACE-
inhibitors, and others, may be a good candidate for a TMR.   
 
Family Planning 
Family planning is also recommended to improve 
preconception health (Table 3).
10,11  
  Pharmacists are well-
suited to take into account many aspects of care, such as 
concurrent drug therapies, folic acid use, and concurrent 
disease states when developing a reproductive life plan with 
patients to facilitate family planning.
28
  Pharmacists can assist 
patients with identifying contraceptive products or methods 
most appropriate and acceptable for them and educate on 
proper and consistent use.
29
  In addition, women who have 
any of the health risks included in Table 4 should be identified 
by pharmacists and counseled on effective contraceptive 
options and consistent, correct use.  Pharmacists also can 
discuss other considerations such as proper nutrition and 
optimal birth spacing (18 to 59 months between last delivery 
and conception of the next pregnancy)
30
 with patients. 
 
Vaccinations 
Pharmacists play an important role as immunizers. One 
particular advantage of pharmacists providing immunizations 
is the accessibility of the pharmacist when traditional 
physician’s office-based practices are closed.
31   
Women 
receiving preconception care may appreciate the availability 
of the pharmacist to provide appropriate immunizations as 
indicated. Additionally, beyond the immunization itself 
potentially generating revenue for the pharmacy, MTM 
reimbursement may be available for the clinical decision 
making process to ensure that the immunization is 
appropriate.  
 
The CDC and SPCC include hepatitis B and rubella vaccination 
among the proven interventions.  To reduce the risk of 
perinatal transmission and long-term consequences of 
hepatitis B, it is recommended that prior to conception, 
women who are at risk for contracting it should consider 
vaccination.  It is also recommended that women who are 
seronegative to rubella should consider MMR vaccination 
prior to conception to avoid congenital rubella syndrome 
which may result from contracting rubella in the first 
trimester.
 10,11,24
  Once receiving the live vaccine, women 
should avoid conception for 28 days; the vaccine is 
contraindicated during pregnancy.
32
 While not specifically 
mentioned in the 14 proven interventions, other vaccines 
may be indicated for women during pregnancy or the 
preconception period per the Advisory Committee on 
Immunization Practices (ACIP) adult immunization schedule
33
 
and guidelines on vaccine use during pregnancy.
32
 
 
Screening, Support, and Referrals 
Point-of-care testing (POCT) is used in MTM to help with 
disease screening, disease assessment, and patient 
monitoring, and is possible for pharmacist or pharmacy 
technicians to perform in an outpatient setting.
34 
 Although 
pharmacists are not trained as diagnosticians, POCT has been 
used to assist pharmacists in screening populations for 
disease or risk of disease.
35
 Given the accessibility of the 
pharmacist, risk and disease screening in the pharmacy may 
be valuable for certain patient populations. Obviously, 
counseling from the pharmacist could ensue to provide 
appropriate clinical recommendations. However, some 
instances remain when it is outside of the pharmacist’s scope 
of practice or expertise to provide appropriate screening, 
assessment, or counseling for a given disease state. It is at 
this time that the Core Elements of an MTM Service Model 
framework describes that the pharmacist should be making 
appropriate referrals to ensure optimal care of the patient.
36
  
Aspects of preconception care where screening and 
pharmacist intervention could be appropriate include testing 
for HIV/AIDS, sexually transmitted infections (STIs), 
hypothyroidism, obesity, and maternal phenylketonuria 
(PKU).  
 
To reduce the risk of perinatal HIV infection, it is 
recommended that women be screened and treated for 
HIV/AIDS.  Women should also be screened and treated for 
STIs to minimize serious risks to mother and child.
10,11
   
 
Untreated or undertreated hypothyroidism also poses serious 
adverse fetal and maternal outcomes; the American 
Association of Clinical Endocrinologists recommends routinely 
screening women for thyroid dysfunction by obtaining TSH 
measurements before conception or during early pregnancy.  
A woman’s dose of levothyroxine must generally be increased 
for proper fetal development during the first trimester, and 
more frequent monitoring of serum TSH is warranted 
throughout pregnancy.
10,11,37 
 Additionally, pharmacists who 
can order laboratory testing as part of a collaborative practice 
agreement  may want to pay careful consideration to the 
above testing recommendations when caring for patients 
who are intending to become pregnant. 
 
Body mass index (BMI) should be calculated at least annually 
for women of childbearing age.  Obese women (BMI≥30) 
should receive counseling on appropriate weight loss and 
nutritional intake, including calorie and portion control and 
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physical activity that can be safely continued in pregnancy. 
Women should be counseled that conception should be 
delayed until optimal weight is achieved to reduce the risk of 
pregnancy complications and birth defects or fetal 
death.
10,11,24
  
 
Finally, it is important to identify women who were 
diagnosed with PKU in childhood and have since relaxed 
dietary restrictions.  Increased levels of phenylalanine can 
result in serious risks to the fetus.  Women with PKU should 
be counseled to resume a restricted diet to achieve 
phenylalanine levels <6 mg/dL at least 3 months before 
conception and maintain phenylalanine levels of 2-6 mg/dL 
during pregnancy.
10,11,24,25
  
 
Tobacco, Alcohol, and Substance Abuse 
Pharmacists have achieved positive outcomes when 
conducting smoking cessation services.
38,39  
Although these 
services are not limited to women who may become 
pregnant, there may be an additional level of concern and/or 
urgency when providing smoking cessation services as a facet 
of preconception care.  If medications are recommended, 
either over-the-counter or as a prescription, a pharmacist 
may be able to bill for making such a recommendation.  
 
Much published literature indicates that smoking results in 
negative consequences to maternal health and perinatal 
outcomes.  Prior to conception, women should be 
encouraged to stop smoking.  The highest cessation rates are 
seen in counseling with both behavioral and educational 
interventions.  Data indicate that pharmacological smoking 
cessation aids are safe and effective in reproductive-age 
women; there is insufficient data on their use among women 
who are pregnant or nursing.  Risks and benefits of smoking 
cessation therapy for a woman who is pregnant or nursing 
must be carefully considered using the most current data 
available.
10,11,24,40  
 
Women should additionally be counseled regarding use of 
recreational drugs or alcohol during the preconception period 
or pregnancy.  Use of these substances may impair fertility, 
result in pregnancy complications, and/or cause grave harm 
to the fetus.  Data indicate that even light drinking may have 
harmful effects to the fetus, so pregnant women should avoid 
alcohol completely.
10,11,24,41 
 
Opportunities for Pharmacist Intervention via CMR  
With the growth of MTM in recent years, many more 
pharmacists are completing CMRs as a part of their regular 
job responsibilities. However, if a pharmacist is not aware of 
both the need and opportunity for appropriate preconception 
clinical considerations, he or she may not make appropriate 
care interventions during the CMR. If a pharmacist discovers 
targeted interventions related to preconception care that 
accompany other unrelated targeted interventions, it may be 
appropriate to recommend a CMR instead of pursuing a TMR 
with a patient. Additionally, a pharmacist may discover 
several preconception-related interventions that are 
appropriate, and given the volume of discussion necessary, 
may find it valuable to schedule a CMR to review multiple 
interventions. Furthermore, a patient with many medications 
or multiple disease states may require education and clinical 
support that would warrant a CMR. 
 
For example, due to the complexity of the disease state, a 
woman with diabetes may  need a CMR in the preconception 
or interconception period.   Women with diabetes poorly 
controlled at the time of conception and their offspring are at 
risk for serious complications.  Therefore, in the months 
before conception women should strive to maintain a 
consistent blood glucose with HbA1C levels no higher than 
6%,
42
 and should look to do so using treatments that would 
be safe in pregnancy.  As opposed to a more standard 7% 
HbA1C target,
43
 the stringent 6% goal may be more difficult 
to achieve, especially when balancing hypoglycemia risks. 
Additionally, preferred pharmacologic and non-
pharmacologic treatments in the preconception period may 
be different than the patient’s current therapy. Not knowing 
about a woman’s intent to become pregnant could result in a 
pharmacist recommending suboptimal or even unsafe 
therapies in this instance. Therefore, given the number and 
scope of changes and education related to all medications, a 
CMR may certainly be warranted. Women with diabetes 
should also be educated about folic acid supplementation as 
discussed above and receive information specific to nutrition 
and management of diabetes during pregnancy, including 
physical activity.
10,11,24,42
 
 
Conclusion 
Opportunities exist within the current MTM environment to 
improve preconception care. Pharmacists currently provide 
similar patient care interventions, and are well-positioned to 
provide clinical preconception care services to patients.  
Furthermore, opportunities for patient care may be missed 
by pharmacists who are unaware of the need for 
intervention. Depending on clinical pharmacy service 
contracts and billing opportunities, some clinical pharmacy 
opportunities may not only benefit patients, but may also 
generate revenue and therefore be financially sustainable. 
Pharmacists should consider incorporating preconception 
services as a part of a larger MTM and clinical service 
paradigm.  
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Table 1.  Key roles for pharmacists in preconception health
29,44-46
 
 
 
 
 
Table 2   Preconception health goals
 
(CDC/SPPC)
10,11 
 
 
 
 
 
 
 
 
 
 
 
 
Partner with patients in family planning 
Provide education, counseling, and/or medication therapy management for patients as appropriate on 
proven preconception health interventions 
Administer needed vaccinations to patients per state law 
Collaborate with other healthcare providers to ensure all patients’ preconception health needs are met 
Utilize drug infromation skills to retrieve and interpret literature or provide information for patients and 
other healthcare professionals regarding medication use and drug toxicity during pregnancy or available 
data on animal reproduction tests 
Raise awareness about preconception care among patients and other healthcare professionals 
Advocacy 
Research 
Goal 1 
•Improve the 
knowledge, attitudes 
and behaviors of men 
and women related to 
preconception health. 
Goal 2 
•Assure that all 
women of child-
bearing age in the 
U.S. receive 
preconception care 
services that will 
enable them to enter 
pregnancy in optimal 
health. 
Goal 3 
•Reduce risks indicated 
by a previous adverse 
pregnancy outcome 
through interventions 
during the 
interconception 
period. 
Goal 4 
•Reduce the disparities 
in adverse pregnancy 
outcomes. 
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Table 3.  Recommendations to improve preconception health
10,11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
•Counsel all patients to have a reproductive life  plan and to implement via their preferred family 
planning methods 
1.  Individual responsibility across the life span   
•Increase patient education and use of health services 
2.  Consumer awareness   
•Provide risk assessment and counseling regarding preconception health to all women of 
childbearing age 
3.  Preventive visits   
•Increase proportion of women receiving necessary interventions identified through screening 
4.  Interventions for identified risks     
•Intensive interventions targeted to women who experienced adverse  outcomes in prior 
pregnancy 
5.  Interconception care  
•Before conception, provide a clinical visit to couples planning a pregnancy  
6.  Pre-pregnancy check-ups   
•Integrate preconception health with existing public  health programs 
8.  Public health programs and strategies  
•Improve access to preventive services among those with low income 
7.  Health coverage for low-income women  
•Enhance knowledge about preconception care 
9.  Research   
•Monitor via public health surveillance and other research  mechanisms  
10. Monitoring improvements    
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Table 4.  Fourteen proven interventions for preconception care
10,11 
 
 
 
 
 
 
Maternal 
conditions 
•Diabetes 
•Hypothyroidism 
•Phenylketonuria 
•Obesity 
Teratogenic 
medications 
•Antiepileptic drugs 
•Warfarin 
•Isotretinoin 
Counseling 
•Folic acid 
•Tobacco 
•Alcohol/illicit drugs 
Screening 
•HIV/AIDS 
•Sexually transmitted infections 
Vaccinations 
•Hepatitis B 
•Rubella 
